Corticosterone
Suppliers
Names
[ CAS No. ]:
50-22-6
[ Name ]:
Corticosterone
[Synonym ]:
Pregn-4-ene-3,20-dione, 11β,21-dihydroxy-
CORTICOSTERONE
Pregn-4-ene-3,20-dione, 11β, 21-dihydroxy-
Pregn-4-ene-3,20-dione, 11,21-dihydroxy-, (11β)-
EINECS 200-019-6
4-Pregnene-11b,21-diol-3,20-dione
11b,21-Dihydroxy-4-pregnene-3,20-dione
MFCD00037715
(11β)-11,21-Dihydroxypregn-4-ene-3,20-dione
Pregn-4-ene-3,20-dione, 11,21-dihydroxy-, (11-β)- (9CI)
11b,21-Dihydroxyprogesterone
(8S,9S,10R,11S,13S,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
(11b)-11,21-Dihydroxypregn-4-ene-3,20-dione
11b,21-Dihydroxypregn-4-ene-3,20-dione
Pregn-4-ene-3,20-dione, 11-β,21-dihydroxy-
4-08-00-02907 (Beilstein Handbook Reference)
4-Pregnene-11β,21-diol-3,20-dione
Chemical & Physical Properties
[ Density]:
1.2±0.1 g/cm3
[ Boiling Point ]:
529.2±50.0 °C at 760 mmHg
[ Melting Point ]:
179-183 °C(lit.)
[ Molecular Formula ]:
C21H30O4
[ Molecular Weight ]:
346.461
[ Flash Point ]:
288.0±26.6 °C
[ Exact Mass ]:
346.214417
[ PSA ]:
74.60000
[ LogP ]:
1.76
[ Vapour Pressure ]:
0.0±3.2 mmHg at 25°C
[ Index of Refraction ]:
1.576
[ Storage condition ]:
Store at RT
[ Stability ]:
Stable, but light sensitive. Incompatible with strong oxidizing agents.
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- GM7650000
- CHEMICAL NAME :
- Corticosterone
- CAS REGISTRY NUMBER :
- 50-22-6
- BEILSTEIN REFERENCE NO. :
- 2339601
- LAST UPDATED :
- 199703
- DATA ITEMS CITED :
- 13
- MOLECULAR FORMULA :
- C21-H30-O4
- MOLECULAR WEIGHT :
- 346.51
- WISWESSER LINE NOTATION :
- L E5 B666 OV MUTJ A1 CQ E1 FV1Q
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 14 mg/kg
- SEX/DURATION :
- female 19-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 525 mg/kg
- SEX/DURATION :
- female 12-18 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - endocrine system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 500 mg/kg
- SEX/DURATION :
- female 8-17 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 84 mg/kg
- SEX/DURATION :
- female 16-22 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - behavioral
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 1472 mg/kg
- SEX/DURATION :
- female 11-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 400 mg/kg
- SEX/DURATION :
- female 11-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 100 mg/kg
- SEX/DURATION :
- female 13 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 400 mg/kg
- SEX/DURATION :
- female 11-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 40 mg/kg
- SEX/DURATION :
- female 11 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 80 mg/kg
- SEX/DURATION :
- female 11 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
MUTATION DATA
- TYPE OF TEST :
- DNA inhibition
- TEST SYSTEM :
- Bird - chicken Embryo
- DOSE/DURATION :
- 1500 pmol/L
- REFERENCE :
- NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869- Volume(issue)/page/year: 257,804,1975
Safety Information
[ Symbol ]:
GHS07
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H317
[ Precautionary Statements ]:
P280
[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves
[ Hazard Codes ]:
Xi,N,Xn,T
[ Risk Phrases ]:
R43
[ Safety Phrases ]:
S36
[ RIDADR ]:
2811.0
[ WGK Germany ]:
3
[ RTECS ]:
GM7650000
[ Hazard Class ]:
6.1
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Articles
Br. J. Pharmacol. 172(3) , 857-68, (2015)
AT1 receptor blockers (ARBs) represent an approach for treating metabolic syndrome due to their potency in reducing hypertension, body weight and onset of type 2 diabetes. The mechanism underlying ARB...
PLoS ONE 9(5) , e98398, (2014)
Osteopontin (OPN) is a multifunctional extracellular matrix (ECM) protein involved in multiple physiological processes. OPN expression is dramatically increased in visceral adipose tissue in obesity a...
J. Appl. Physiol. 117(7) , 765-76, (2014)
Obstructive sleep apnea causes chronic intermittent hypoxia (IH) and is associated with impaired glucose metabolism, but mechanisms are unknown. Carotid bodies orchestrate physiological responses to h...